Evolus, Inc. – NASDAQ:EOLS

Add to watchlist

$7.1

-3.99

-35.98%

Market closed

Open in about 14 hours

-5.78%

month

-5.78%

quarter

+9.26%

year

Market Cap	694.00M
Enterprise value	20.96M

P/E	-6.25
EV/Sales	0.14
EV/EBITDA	-0.34
Price/Sales	N/A
Price/Book	0.02
PEG ratio	0.15
EPS	-1.05

Revenue	219.00M
EBITDA	-37.75M
Income	-60.00M
Revenue Q/Q	42.21%
Revenue Y/Y	40.00%

Profit margin	-50%
Oper. margin	-38.74%
Gross margin	62.4%
EBIT margin	-38.74%
EBITDA margin	-17.24%

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Evolus, Inc. (NASDAQ:EOLS): Profit margin
Jun 2023	49.34M	-18.14M	-36.76%
Sep 2023	49.32M	-16.92M	-34.31%
Dec 2023	60.99M	-11.83M	-19.4%
Mar 2024	59.33M	-13.10M	-22.09%

Evolus Financials Estimate

Q Y

Evolus, Inc. (NASDAQ:EOLS): Analyst Estimates
Mar 2024	59.33M	-13.10M	-22.09%
Sep 2025	132.55M	1.60M	1.21%
Oct 2025	91.2M	2.41M	2.64%
Dec 2025	99.8M	8.64M	8.66%

Analysts Price target
Financials & Ratios estimates

Evolus, Inc. (NASDAQ:EOLS): Debt to assets
Jun 2023	168983000	175.94M	104.12%
Sep 2023	167971000	187.33M	111.53%
Dec 2023	188998000	209.68M	110.95%
Mar 2024	226176000	207.73M	91.85%

Evolus, Inc. (NASDAQ:EOLS): Cash Flow
Jun 2023	-13.31M	-216K	23.82M
Sep 2023	-34.82M	-1.26M	21.11M
Dec 2023	813K	-361K	23.52M
Mar 2024	-10.61M	-797K	45.66M

Evolus alternative data

Social Media

🎓 Academy: How impactful can social media data be in investment decisions

Evolus, Inc. (NASDAQ:EOLS): Employee count
Aug 2023	224
Sep 2023	215
Oct 2023	215
Nov 2023	215
Dec 2023	246
Jan 2024	246
Feb 2024	246
Mar 2024	273
Apr 2024	273
May 2024	273
Jun 2024	279
Jul 2024	279

Evolus
Hedge Funds Holdings Q1 2023

13.69% -38.37%

of EOLS is owned by hedge funds

71 -44

hedge funds hold EOLS stock

7.67M -21.57M

shares is hold by hedge funds

EOLS hedge funds holdings changes

Evolus, Inc. (NASDAQ:EOLS): Insider trades (number of shares)
Period	Buy	Sel
Jan 2024	0	11931
Feb 2024	0	11348
Mar 2024	0	136077
May 2024	0	60276
Jun 2024	0	478932
Aug 2024	0	5631
Sep 2024	0	3276
Dec 2024	0	14340

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Sale	23 Dec 2024	AVELAR RUI officer: See Remarks officer: See Remarks	Common Stock	2,252	$10.85	$24,439
Sale	23 Dec 2024	BEAVER SANDRA officer: Chief Financial Officer officer: Chief Financial Officer	Common Stock	1,586	$10.85	$17,211
Sale	23 Dec 2024	MOATAZEDI DAVID director, officer..	Common Stock	10,502	$10.85	$113,968
Sale	6 Sep 2024	BEAVER SANDRA officer: Chief Financial Officer officer: Chief Financial Officer	Common Stock	3,276	$14.98	$49,074
Sale	30 Aug 2024	YAMAGISHI-DRESSLER TOMOKO officer: Chief Marketing Officer officer: Chief Marketing Officer	Common Stock	5,631	$15.85	$89,251
Option	6 Jun 2024	MOATAZEDI DAVID director, officer..	Stock Option (Right to Buy)	175,940	$7.28	$1,280,843
Option	6 Jun 2024	MOATAZEDI DAVID director, officer..	Common Stock	175,940	$7.28	$1,280,843
Sale	6 Jun 2024	MOATAZEDI DAVID director, officer..	Common Stock	175,940	$12.59	$2,214,557
Option	5 Jun 2024	MOATAZEDI DAVID director, officer..	Common Stock	155,278	$5.46	$847,818
Sale	5 Jun 2024	MOATAZEDI DAVID director, officer..	Common Stock	155,278	$12.92	$2,006,502

Evolus
Earnings Call Transcripts

Quarter	Transcript
Q1 2024 7 May 2024	Q1 2024 Earnings Call Transcript
Q4 2023 7 Mar 2024	Q4 2023 Earnings Call Transcript
Q3 2023 7 Nov 2023	Q3 2023 Earnings Call Transcript
Q2 2023 2 Aug 2023	Q2 2023 Earnings Call Transcript

EOLS earnings call transcripts

Evolus
Executives

Insider	Age	Compensation
Mr. David Moatazedi (1978) Pres, Chief Executive Officer & Director	47	$1,250,000
Ms. Lauren P. Silvernail (1958) Chief Financial Officer & Executive Vice President of Corporation Devel.	67	$633,180
Dr. Rui Avelar Dip.SportMed, M.D., C.CFP (1962) Chief Medical Officer and Head of R&D	63	$631,260

Evolus
Latest News

Friday, 13 December 2024
16:05	Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	businesswire.com
Monday, 18 November 2024
10:55	Here's Why Evolus (EOLS) Could be Great Choice for a Bottom Fisher	zacks.com
Thursday, 14 November 2024
10:35	Down -29.8% in 4 Weeks, Here's Why You Should You Buy the Dip in Evolus (EOLS)	zacks.com
Wednesday, 6 November 2024
19:26	Evolus, Inc. (EOLS) Reports Q3 Loss, Misses Revenue Estimates	zacks.com
16:05	Evolus Reports Third Quarter 2024 Results	businesswire.com
Friday, 1 November 2024
08:00	Evolus to Participate in Stifel 2024 Healthcare Conference	businesswire.com
Thursday, 31 October 2024
14:02	Evolus Announces EU Approval of Estyme® Injectable Hyaluronic Acid Gels Under New Medical Device Regulation	businesswire.com
Wednesday, 30 October 2024
11:06	Will Evolus, Inc. (EOLS) Report Negative Earnings Next Week? What You Should Know	zacks.com
Friday, 11 October 2024
22:53	Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	businesswire.com
Friday, 27 September 2024
21:00	Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	businesswire.com
Friday, 9 August 2024
16:30	Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	businesswire.com
Wednesday, 31 July 2024
22:22	Evolus, Inc. (EOLS) Q2 2024 Earnings Call Transcript	seekingalpha.com
19:46	Evolus, Inc. (EOLS) Reports Q2 Loss, Tops Revenue Estimates	zacks.com
16:09	Evolus reports first-ever adjusted profit in Q2 fueled by strong sales of Botox rival	reuters.com
16:05	Evolus, A Medical Aesthetics Player, Becomes Profitable — Two Quarters Early	investors.com
Wednesday, 17 July 2024
08:00	Evolus to Report Second Quarter Financial Results on July 31, 2024	businesswire.com
Monday, 24 June 2024
08:00	Evolus Announces Submission of Premarket Approval Application to the U.S. Food and Drug Administration for First Two Evolysse™ Dermal Filler Products	businesswire.com
Wednesday, 12 June 2024
08:00	Evolus Broadens International Presence with Launch of Nuceiva® (botulinum toxin type A) in Spain	businesswire.com
Friday, 7 June 2024
17:00	Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	businesswire.com
Tuesday, 21 May 2024
12:01	Evolus (EOLS) Releases Favorable Dermal Fillers Study Data	zacks.com
Monday, 20 May 2024
08:30	Evolus Announces Positive Data from Pivotal Trial for First Two Evolysse™ Dermal Filler Products at 2024 SCALE Meeting	businesswire.com
Wednesday, 15 May 2024
08:30	Evolus Celebrates Fifth Anniversary of Launching its Flagship Product Jeuveau® at the Women's Wear Daily Beauty CEO Summit	businesswire.com
Friday, 10 May 2024
18:55	Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	businesswire.com
09:10	Evolus' Sandra Beaver Named Orange County Business Journal's Public Company CFO of the Year	businesswire.com
Tuesday, 7 May 2024
23:27	Evolus, Inc. (EOLS) Q1 2024 Earnings Call Transcript	Seeking Alpha
19:35	Evolus, Inc. (EOLS) Reports Q1 Loss, Tops Revenue Estimates	Zacks Investment Research
Friday, 3 May 2024
08:26	4 Stocks to Keep a Tab on for Amazing Earnings Acceleration	Zacks Investment Research
Thursday, 25 April 2024
08:01	3 Top Stocks to Invest in for Amazing Earnings Acceleration	Zacks Investment Research
Tuesday, 23 April 2024
16:30	Evolus to Report First Quarter Financial Results on May 7, 2024	Business Wire
Wednesday, 20 March 2024
14:05	Evolus: Smooth Progress As Management Targets $700m Aesthetics Franchise Revenues By 2028	Seeking Alpha

Ideas & Opinions

Seeking Alpha 21 Jul 2025

Evolus - A Slightly Risky Buy Ahead Of Q2 Earnings
Seeking Alpha 10 Jun 2025

Tiny Phathom Pharmaceuticals Just An Got FDA Blessing And Big-Time Upside: Buy
Seeking Alpha 14 Jan 2025

Evolus: Still Bullish, But Business Faces Tricky Challenges In '25
Seeking Alpha 22 May 2024

Evolus: Chiseling Away At The Aesthetic Market
Seeking Alpha 19 Sep 2023

Evolus: Gaining Market Share
Seeking Alpha 29 Jun 2023

Evolus: Botox Copy Cat In A Challenging Aesthetic Market
Seeking Alpha 19 Apr 2023

Evolus: Capitalizing On The Growth Of Aesthetics Market
Seeking Alpha 7 Feb 2023

Evolus: Extra Strength Dose Data Provides Additional Offering Expansion For Jeuveau
Seeking Alpha 24 Aug 2022

Revance Therapeutics: More Risk To Sept. 8 PDUFA Than It Seems

Frequently Asked Questions (FAQ)

What's the price of Evolus stock today?

One share of Evolus stock can currently be purchased for approximately $7.1.
When is Evolus's next earnings date?

Unfortunately, Evolus's (EOLS) next earnings date is currently unknown.
Does Evolus pay dividends?

No, Evolus does not pay dividends.
How much money does Evolus make?

Evolus has a market capitalization of 694.00M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 35.98% to 202.09M US dollars.
What is Evolus's stock symbol?

Evolus, Inc. is traded on the NASDAQ under the ticker symbol "EOLS".
What is Evolus's primary industry?

Company operates in the Healthcare sector and Drug Manufacturers - Specialty & Generic industry.
How do i buy shares of Evolus?

Shares of Evolus can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Evolus's key executives?
Evolus's management team includes the following people:
- Mr. David Moatazedi Pres, Chief Executive Officer & Director(age: 47, pay: $1,250,000)
- Ms. Lauren P. Silvernail Chief Financial Officer & Executive Vice President of Corporation Devel.(age: 67, pay: $633,180)
- Dr. Rui Avelar Dip.SportMed, M.D., C.CFP Chief Medical Officer and Head of R&D(age: 63, pay: $631,260)
How many employees does Evolus have?

As Jul 2024, Evolus employs 279 workers, which is 2% more then previous quarter.
When Evolus went public?

Evolus, Inc. is publicly traded company for more then 7 years since IPO on 8 Feb 2018.
What is Evolus's official website?

The official website for Evolus is evolus.com.
Where are Evolus's headquarters?

Evolus is headquartered at 520 Newport Center Drive, Newport Beach, CA.
How can i contact Evolus?

Evolus's mailing address is 520 Newport Center Drive, Newport Beach, CA and company can be reached via phone at +94 92844555.

Evolus, Inc.

evolus.com

Exchange:

NASDAQ

Full time employees:

322

Industry:

Drug Manufacturers - Specialty & Generic

Sector:

Healthcare

Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorporated in 2012 and is headquartered in Newport Beach, California.

+94 92844555

520 Newport Center Drive
Newport Beach, CA 92660

CIK: 0001570562
ISIN: US30052C1071
CUSIP: 30052C107